These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 30737678)

  • 1. Influence of proton pump inhibitors on microbiota in chronic liver disease patients.
    Yamamoto K; Ishigami M; Honda T; Takeyama T; Ito T; Ishizu Y; Kuzuya T; Hayashi K; Goto H; Hirooka Y
    Hepatol Int; 2019 Mar; 13(2):234-244. PubMed ID: 30737678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of proton pump inhibitor or rebamipide use on gut microbiota of rheumatoid arthritis patients.
    Kim JW; Jeong Y; Park SJ; Jin H; Lee J; Ju JH; Ji GE; Park SH
    Rheumatology (Oxford); 2021 Feb; 60(2):708-716. PubMed ID: 32789440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proton pump inhibitor use significantly increases the risk of spontaneous bacterial peritonitis in 1965 patients with cirrhosis and ascites: a propensity score matched cohort study.
    Min YW; Lim KS; Min BH; Gwak GY; Paik YH; Choi MS; Lee JH; Kim JJ; Koh KC; Paik SW; Yoo BC; Rhee PL
    Aliment Pharmacol Ther; 2014 Sep; 40(6):695-704. PubMed ID: 25078671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of proton pump inhibitors on the intestinal microbiota in chronic hepatitis C patients.
    Wellhöner F; Döscher N; Tergast TL; Vital M; Plumeier I; Kahl S; Potthoff A; Manns MP; Maasoumy B; Wedemeyer H; Cornberg M; Pieper DH; Heidrich B
    Scand J Gastroenterol; 2019 Aug; 54(8):1033-1041. PubMed ID: 31361979
    [No Abstract]   [Full Text] [Related]  

  • 5. Proton pump inhibitors do not increase the risk for recurrent spontaneous bacterial peritonitis in patients with cirrhosis.
    Kim JH; Lim KS; Min YW; Lee H; Min BH; Rhee PL; Kim JJ; Koh KC; Paik SW
    J Gastroenterol Hepatol; 2017 May; 32(5):1064-1070. PubMed ID: 28449345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proton pump inhibitors as a risk factor for hepatic encephalopathy and spontaneous bacterial peritonitis in patients with cirrhosis with ascites.
    Dam G; Vilstrup H; Watson H; Jepsen P
    Hepatology; 2016 Oct; 64(4):1265-72. PubMed ID: 27474889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gut Microbiota Composition Before and After Use of Proton Pump Inhibitors.
    Hojo M; Asahara T; Nagahara A; Takeda T; Matsumoto K; Ueyama H; Matsumoto K; Asaoka D; Takahashi T; Nomoto K; Yamashiro Y; Watanabe S
    Dig Dis Sci; 2018 Nov; 63(11):2940-2949. PubMed ID: 29796911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic review: the effects of proton pump inhibitors on the microbiome of the digestive tract-evidence from next-generation sequencing studies.
    Macke L; Schulz C; Koletzko L; Malfertheiner P
    Aliment Pharmacol Ther; 2020 Mar; 51(5):505-526. PubMed ID: 31990420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of proton pump inhibitor therapy with spontaneous bacterial peritonitis in cirrhotic patients with ascites.
    Bajaj JS; Zadvornova Y; Heuman DM; Hafeezullah M; Hoffmann RG; Sanyal AJ; Saeian K
    Am J Gastroenterol; 2009 May; 104(5):1130-4. PubMed ID: 19337238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Proton Pump Inhibitors on the Gastrointestinal Microbiota in Gastroesophageal Reflux Disease.
    Shi YC; Cai ST; Tian YP; Zhao HJ; Zhang YB; Chen J; Ren RR; Luo X; Peng LH; Sun G; Yang YS
    Genomics Proteomics Bioinformatics; 2019 Feb; 17(1):52-63. PubMed ID: 31028880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proton pump inhibitor use increases mortality and hepatic decompensation in liver cirrhosis.
    De Roza MA; Kai L; Kam JW; Chan YH; Kwek A; Ang TL; Hsiang JC
    World J Gastroenterol; 2019 Sep; 25(33):4933-4944. PubMed ID: 31543684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Restoration of the gut microbiota is associated with a decreased risk of hepatic encephalopathy after TIPS.
    Li M; Li K; Tang S; Lv Y; Wang Q; Wang Z; Luo B; Niu J; Zhu Y; Guo W; Bai W; Wang E; Xia D; Wang Z; Li X; Yuan J; Yin Z; Trebicka J; Han G
    JHEP Rep; 2022 May; 4(5):100448. PubMed ID: 35313729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proton pump inhibitor intake neither predisposes to spontaneous bacterial peritonitis or other infections nor increases mortality in patients with cirrhosis and ascites.
    Mandorfer M; Bota S; Schwabl P; Bucsics T; Pfisterer N; Summereder C; Hagmann M; Blacky A; Ferlitsch A; Sieghart W; Trauner M; Peck-Radosavljevic M; Reiberger T
    PLoS One; 2014; 9(11):e110503. PubMed ID: 25369194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral microbiome alterations of healthy volunteers with proton pump inhibitor.
    Mishiro T; Oka K; Kuroki Y; Takahashi M; Tatsumi K; Saitoh T; Tobita H; Ishimura N; Sato S; Ishihara S; Sekine J; Wada K; Kinoshita Y
    J Gastroenterol Hepatol; 2018 May; 33(5):1059-1066. PubMed ID: 29105152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose proton pump inhibitor treatment is associated with a higher mortality in cirrhotic patients: A multicentre study.
    Yoon JS; Hong JH; Park SY; Kim SU; Kim HY; Kim JY; Hur MH; Park MK; Lee YB; Lee HA; Kim GA; Sinn DH; Park SJ; Lee YJ; Kim YJ; Yoon JH; Lee JH
    Aliment Pharmacol Ther; 2024 Apr; 59(8):973-983. PubMed ID: 38389319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proton Pump Inhibitor Use and Complications of Cirrhosis Are Linked With Distinct Gut Microbial Bacteriophage and Eukaryotic Viral-Like Particle Signatures in Cirrhosis.
    Peña Rodríguez M; Fagan A; Sikaroodi M; Gillevet PM; Bajaj JS
    Clin Transl Gastroenterol; 2024 Feb; 15(2):e00659. PubMed ID: 37937851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proton Pump Inhibitors: Risks and Rewards and Emerging Consequences to the Gut Microbiome.
    Singh A; Cresci GA; Kirby DF
    Nutr Clin Pract; 2018 Oct; 33(5):614-624. PubMed ID: 30071147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of the gut microbiome between long-term users and non-users of proton pump inhibitors.
    Clooney AG; Bernstein CN; Leslie WD; Vagianos K; Sargent M; Laserna-Mendieta EJ; Claesson MJ; Targownik LE
    Aliment Pharmacol Ther; 2016 May; 43(9):974-84. PubMed ID: 26923470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomarkers for oralization during long-term proton pump inhibitor therapy predict survival in cirrhosis.
    Horvath A; Rainer F; Bashir M; Leber B; Schmerboeck B; Klymiuk I; Groselj-Strele A; Durdevic M; Freedberg DE; Abrams JA; Fickert P; Stiegler P; Stadlbauer V
    Sci Rep; 2019 Aug; 9(1):12000. PubMed ID: 31427714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Proton Pump Inhibitors on the Gastric Mucosa-Associated Microbiota in Dyspeptic Patients.
    Paroni Sterbini F; Palladini A; Masucci L; Cannistraci CV; Pastorino R; Ianiro G; Bugli F; Martini C; Ricciardi W; Gasbarrini A; Sanguinetti M; Cammarota G; Posteraro B
    Appl Environ Microbiol; 2016 Nov; 82(22):6633-6644. PubMed ID: 27590821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.